A systematic review of validated methods for identifying systemic lupus erythematosus (SLE) using administrative or claims data

Vaccine

Volumn 31, Issue S10, 2013, Pages

  Moores, Kevin G ^a   Sathe, Nila A ^b  

^a UNIVERSITY OF IOWA   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Administrative database; Algorithm validation; ICD 9; Incidence calculation; Positive predictive value (PPV); Systemic lupus erythematosus (SLE)

Indexed keywords

ALGORITHM; BILLING AND CLAIMS; HOSPITALIZATION; HUMAN; ICD-9; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICAL RECORD; MEDLINE; PREDICTIVE VALUE; PREGNANCY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION STUDY;

ACR; ADMINISTRATIVE DATABASE; ALGORITHM VALIDATION; AMERICAN COLLEGE OF RHEUMATOLOGY; CI; CONFIDENCE INTERVAL; CPT; CURRENT PROCEDURAL TERMINOLOGY; END STAGE RENAL DISEASE; ESRD; ICD; ICD-9; INCIDENCE CALCULATION; INTERNATIONAL CLASSIFICATION OF DISEASES; KAISER PERMANENTE NORTHERN CALIFORNIA; KPNC; N; NOT REPORTED; NR; NUMBER; POSITIVE PREDICTIVE VALUE (PPV); SLE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS (SLE); US RENAL DATA SYSTEM; USRDS;

ALGORITHMS; DATABASES, FACTUAL; EPIDEMIOLOGIC METHODS; HUMANS; INCIDENCE; INSURANCE CLAIM REVIEW; INTERNATIONAL CLASSIFICATION OF DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84891957389     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.104     Document Type: Review

References (59)

1. Nguyen M., Ball R., Midthun K., Lieu T.A. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012, 21(January (Suppl. 1)):291-297.
2. Carnahan R.M., Moores K.G. Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned. Pharmacoepidemiol Drug Saf 2012, 21(January (Suppl. 1)):82-89.
3. Lieu T.A., Nguyen M.D., Ball R., Martin D.B. Health outcomes of interest for evaluation in the Post-Licensure Rapid Immunization Safety Monitoring Program. Vaccine 2012, 30(April (18)):2824-2830.
4. Tsokos G.C. Systemic lupus erythematosus. N Engl J Med 2011, 365(December (22)):2110-2121.
5. Helmick C.G., Felson D.T., Lawrence R.C., Gabriel S., Hirsch R., Kwoh C.K., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008, 58(January (1)):15-25.
6. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58(January (1)):26-35.
7. Trends in Deaths from Systemic Lupus Erythematosus - United States, 1979-1998. MMWR Morb Mortal Wkly Rep 2002, 51(17):371-374.
8. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(November (11)):1271-1277.
9. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(September (9)):1725.
10. McPheeters, M, Sathe, N., Jerome, R., Carnahan, R. Methods for Systematic Reviews of Administrative Database Studies Capturing Health Outcomes of Interest Vaccine (submitted for publication).
11. Bernatsky S., Linehan T., Hanly J.G. The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. J Rheumatol 2011, 38(August (8)):1612-1616.
12. Klein N.P., Ray P., Carpenter D., Hansen J., Lewis E., Fireman B., et al. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine 2010, 28(January (4)):1062-1068.
13. Bernatsky S., Joseph L., Pineau C.A., Tamblyn R., Feldman D.E., Clarke A.E. A population-based assessment of systemic lupus erythematosus incidence and prevalence - results and implications of using administrative data for epidemiological studies. Rheumatology (Oxford) 2007, 46(December (12)):1814-1818.
14. Naleway A.L., Davis M.E., Greenlee R.T., Wilson D.A., McCarty D.J. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus 2005, 14(10):862-866.
15. Arbuckle M.R., James J.A., Dennis G.J., Rubertone M.V., McClain M.T., Kim X.R., et al. Rapid clinical progression to diagnosis among African-American men with systemic lupus erythematosus. Lupus 2003, 12(2):99-106.
16. Andrade S.E., Scott P.E., Davis R.L., Li D.K., Getahun D., Cheetham T.C., et al. Validity of health plan and birth certificate data for pregnancy research. Pharmacoepidemiol Drug Saf. 2013, 22(January (1)):7-15.
17. Broder A., Khattri S., Patel R., Putterman C. Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality. J Rheumatol 2011, 38(November (11)):2382-2389.
18. Chibnik L.B., Massarotti E.M., Costenbader K.H. Identification and validation of lupus nephritis cases using administrative data. Lupus 2010, 19(May (6)):741-743.
19. Lim S.S., Jamal A., Bayakly R., Tong L., Drenkard C. The Georgia Lupus Registry: accuracy of hospital discharge data in identifying systemic lupus erythematosus. Arthritis Rheum 2007, 54:S505.
20. Sanchez M.L., Alarcon G.S., McGwin G., Fessler B.J., Kimberly R.P. Can the weighted criteria improve our ability to capture a larger number of lupus patients into observational and interventional studies? A comparison with the American College of Rheumatology criteria. Lupus 2003, 12(6):468-470.
21. Costenbader K.H., Karlson E.W., Mandl L.A. Defining lupus cases for clinical studies: the Boston weighted criteria for the classification of systemic lupus erythematosus. J Rheumatol 2002, 29(December (12)):2545-2550.
22. Katz J.N., Barrett J., Liang M.H., Bacon A.M., Kaplan H., Kieval R.I., et al. Sensitivity and positive predictive value of Medicare Part B physician claims for rheumatologic diagnoses and procedures. Arthritis Rheum 1997, 40(September (9)):1594-1600.
23. Hiraki L.T., Feldman C.H., Liu J., Alarcon G.S., Fischer M.A., Winkelmayer W.C., et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population. Arthritis Rheum 2012, 64(August (8)):2669-2676.
24. Karve S., Candrilli S., Kappelman M.D., Tolleson-Rinehart S., Tennis P., Andrews E. Healthcare utilization and comorbidity burden among children and young adults in the United States with systemic lupus erythematosus or inflammatory bowel disease. J Pediatr 2012, 161(October (4)):662-670.e2.
25. Rogers M.A., Levine D.A., Blumberg N., Fisher G.G., Kabeto M., Langa K.M. Antigenic challenge in the etiology of autoimmune disease in women. J Autoimmun 2012, 38(May (2-3)):J97-J102.
26. Tanzer M., Tran C., Messer K.L., Kroeker A., Herreshoff E., Wickman L., et al. Inpatient healthcare utilization by children and adolescents with systemic lupus erythematosus and kidney involvement. Arthritis Care Res (Hoboken) 2012, (August 16).
27. Vassileva C.M., Swong M.N., Boley T.M., Markwell S.J., Hazelrigg S.R. Influence of systemic lupus erythematosus on procedure selection and outcomes of patients undergoing isolated mitral valve surgery. J Card Surg 2012, 27(January (1)):29-33.
28. Barnabe C., Joseph L., Belisle P., Labrecque J., Edworthy S., Barr S.G., et al. Prevalence of systemic lupus erythematosus and systemic sclerosis in the First Nations population of Alberta, Canada. Arthritis Care Res (Hoboken) 2012, 64(January (1)):138-143.
29. Bernatsky S., Lix L., Hanly J.G., Hudson M., Badley E., Peschken C., et al. Surveillance of systemic autoimmune rheumatic diseases using administrative data. Rheumatol Int 2011, 31(April (4)):549-554.
30. Costenbader K.H., Desai A., Alarcon G.S., Hiraki L.T., Shaykevich T., Brookhart M.A., et al. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 2011, 63(June (6)):1681-1688.
31. Hiraki L.T., Lu B., Alexander S.R., Shaykevich T., Alarcon G.S., Solomon D.H., et al. End-stage renal disease due to lupus nephritis among children in the US, 1995-2006. Arthritis Rheum 2011, 63(July (7)):1988-1997.
32. Sule S., Fivush B., Neu A., Furth S. Increased risk of death in pediatric and adult patients with ESRD secondary to lupus. Pediatr Nephrol 2011, 26(January (1)):93-98.
33. Amend K.L., Turnbull B., Foskett N., Napalkov P., Kurth T., Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 2010, 75(October (15)):1326-1332.
34. Wells D.K., Ward M.M. Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2010, 28(March-April (2)):223-229.
35. Gadalla S.M., Amr S., Langenberg P., Baumgarten M., Davidson W.F., Schairer C., et al. Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based case-control study. Br J Cancer 2009, 100(March (5)):817-821.
36. Lim S.S., Drenkard C., McCune W.J., Helmick C.G., Gordon C., Deguire P., et al. Population-based lupus registries: advancing our epidemiologic understanding. Arthritis Rheum 2009, 61(October (10)):1462-1466.
37. Molloy E.S., Calabrese L.H. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 2009, 60(December (12)):3761-3765.
38. Anderson E., Nietert P.J., Kamen D.L., Gilkeson G.S. Ethnic disparities among patients with systemic lupus erythematosus in South Carolina. J Rheumatol 2008, 35(May (5)):819-825.
39. Molina M.J., Mayor A.M., Franco A.E., Morell C.A., Lopez M.A., Vila L.M. Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico. Ethn Dis 2008, 18(Spring (Suppl. 2)). S2-205-S2-210.
40. Molina M.J., Mayor A.M., Franco A.E., Morell C.A., Lopez M.A., Vila L.M. Prevalence of systemic lupus erythematosus and associated comorbidities in Puerto Rico. J Clin Rheumatol 2007, 13(August (4)):202-204.
41. Parikh-Patel A., White R.H., Allen M., Cress R. Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 2008, 19(October (8)):887-894.
42. Heinlen L.D., McClain M.T., Merrill J., Akbarali Y.W., Edgerton C.C., Harley J.B., et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 2007, 56(July (7)):2344-2351.
43. King J.K., Costenbader K.H. Characteristics of patients with systemic lupus erythematosus (SLE) and non-Hodgkin's lymphoma (NHL). Clin Rheumatol 2007, 26(September (9)):1491-1494.
44. Weng X., Liu L., Barcellos L.F., Allison J.E., Herrinton L.J. Clustering of inflammatory bowel disease with immune mediated diseases among members of a northern California-managed care organization. Am J Gastroenterol 2007, 102(July (7)):1429-1435.
45. Krishnan E., Hubert H.B. Ethnicity and mortality from systemic lupus erythematosus in the US. Ann Rheum Dis 2006, 65(November (11)):1500-1505.
46. Ward M.M., Pajevic S., Dreyfuss J., Malley J.D. Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. Arthritis Rheum 2006, 55(February (1)):74-80.
47. Weir P.T., Harlan G.A., Nkoy F.L., Jones S.S., Hegmann K.T., Gren L.H., et al. The incidence of fibromyalgia and its associated comorbidities: a population-based retrospective cohort study based on International Classification of Diseases, 9th Revision codes. J Clin Rheumatol 2006, 12(June (3)):124-128.
48. Robinson D., Hackett M., Wong J., Kimball A.B., Cohen R., Bala M. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001-2002. Curr Med Res Opin 2006, 22(5):989-1000.
49. Bernstein C.N., Wajda A., Blanchard J.F. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005, 129(3):827-836.
50. James A.H., Bushnell C.D., Jamison M.G., Myers E.R. Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol 2005, 106(September (3)):509-516.
51. Krishnan E. Stroke subtypes among young patients with systemic lupus erythematosus. Am J Med 2005, 118(December (12)):1415.
52. Mauldin J., Cameron H.D., Jeanotte D., Solomon G., Jarvis J.N. Chronic arthritis in children and adolescents in two Indian health service user populations. BMC Musculoskelet Disord 2004, 27(August (5)):30.
53. Ward M.M. Outcomes of hospitalizations for myocardial infarctions and cerebrovascular accidents in patients with systemic lupus erythematosus. Arthritis Rheum 2004, 50(October (10)):3170-3176.
54. Yasmeen S., Wilkins E.E., Field N.T., Sheikh R.A., Gilbert W.M. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med 2001, 10(April (2)):91-96.
55. Ward M.M. Hospital experience and expected mortality in patients with systemic lupus erythematosus: a hospital level analysis. J Rheumatol 2000, 27(September (9)):2146-2151.
56. Ward M.M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42(February (2)):338-346.
57. Ward M.M. Hospital experience and mortality in patients with systemic lupus erythematosus. Arthritis Rheum 1999, 42(May (5)):891-898.
58. Maskarinec G., Katz A.R. Prevalence of systemic lupus erythematosus in Hawaii: is there a difference between ethnic groups?. Hawaii Med J 1995, 54(February (2)):406-409.
59. Calvo-Alen J., Bastian H.M., Straaton K.V., Burgard S.L., Mikhail I.S., Alarcon G. Identification of patient subsets among those presumptively diagnosed with, referred, and/or followed up for systemic lupus erythematosus at a large tertiary care center. Arthritis Rheum 1995, 38(10):1475-1484.